Video

How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?

Author(s):

Davy James, Managing Editor

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

Related Videos
Pharmacist helping a patient with medication -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Patient receiving cancer treatment infusion -- Image credit: UlrikaArt | stock.adobe.com
Related Content
Intravenous Immunoglobulin Plus Rituximab Effective Alternative Option for Refractory Autoimmune Disease Treatment
April 1st 2025

Intravenous Immunoglobulin Plus Rituximab Effective Alternative Option for Refractory Autoimmune Disease Treatment

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Pharmacist, customer or support in shop with medicine, shopping with professional help. Pharmacy, people or together for healthcare service with advice for dosage, pill information for woman with flu
March 31st 2025

Expert Q&A: Role of Pharmacists in COVID-19 Care, Prevention Continues to Evolve

Luke Halpern, Assistant Editor Corey Frederick, PharmD, BCPS, BCIDP, CPh
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Herpes Zoster as an Early Indicator of HIV: Clinical Insights
March 31st 2025

Herpes Zoster as an Early Indicator of HIV: Clinical Insights

Emilia Welch, PharmD, MBA
X-ray image of liver -- Image credit: Sebastian Kaulitzki | stock.adobe.com
March 31st 2025

BEAM-302 Receives FDA IND Clearance for AATD, a Genetic Disorder Affecting the Liver and Lungs

Gillian McGovern, Associate Editor